Skip to main content
OpenTrials
Completed

NCT Number: NCT00588705

The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer

The purpose of this study is to first understand how MSKCC Clinical Genetics Service doctors talk to women with breast cancer about any genetic risks they might carry, and if they help women to think about what they might say, in turn, to their relatives, especially their daughters.

A second part of the study asks women for their opinions about when and how their daughters should be told about any genetic risks.

All of this will help us develop teaching methods to help our doctors improve the way they talk about genetic risk when women with breast cancer have adolescent daughters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Behavior Breast Diseases Breast Neoplasms Communication Counseling Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

12 year–20 year

Sex eligibility

Female

Study type

Observational

Primary location

Memorial Sloan-Kettering Cancer Center

New York, 10065, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women seen in the MSK CGS Service who have a diagnosis of breast cancer or
  • a family history of breast cancer and
  • have biological daughter(s) in the age range 12-20 years will be eligible to participate in Phase I & II.
  • Women who were consented to Phase I will automatically be eligible for Phase II.

Exclusion criteria

  • Women seen in the MSK CGS Service will be ineligible if they have no diagnosis of breast cancer and no family history of breast cancer,
  • do not have a biological daughter,
  • or have a biological daughter fewer than 12 or greater than 20 years(unless they were consented to Phase 1).
  • Women will be ineligible if they are not English speaking,
  • have intellectual or cognitive impairment,
  • or active mental illness rendering them incapable of giving informed consent, such as might occur with active psychosis.

Treatment and study plan

focus group & questionaire

Behavioral

The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.

Primary outcomes

  1. Is a demonstration of the effectiveness of the module in changing the behavior of clinicians after taking part in the communication skills module.

    Time frame: conclusion of study

Secondary outcomes

  1. To examine the views of women about the provision of genetic risk information to their daughters.

    Time frame: conclusion of study

Sponsors and collaborators

Lead sponsor

Memorial Sloan Kettering Cancer Center

Other

Collaborators

  • Monash University

Registry information

Important dates

Study start
2007
Primary completion
2017
Study completion
2017
First posted
Jan 8, 2008
Registry last updated
Jan 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.